Want to see HK:2487 full AI Analyst Report?
2487 Stock Chart & Stats
HK$4.59
-HK$0.09(-1.60%)
At close: 4:00 PM EST
HK$4.59
-HK$0.09(-1.60%)
Day’s Range― - ―
52-Week RangeHK$0.74 - HK$9.19
Previous CloseN/A
Volume1.53M
Average Volume (3M)450.17K
Market Cap
HK$385.77M
Enterprise ValueHK$621.20M
Total Cash (Recent Filing)HK$626.38M
Total Debt (Recent Filing)HK$274.17M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding374,533,900
10 Day Avg. Volume1,076,760
30 Day Avg. Volume450,173
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.52
Price to Sales (P/S)4.01
P/FCF Ratio-4.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)HK$580.00M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthThe sharp acceleration in revenue growth indicates stronger commercial traction and improving demand for the dermatology business. If sustained, expanding sales can improve operating leverage, support investment in the pipeline, and provide a foundation for eventual profitability.
Healthy Gross MarginA gross margin near 46% suggests the company retains meaningful value after direct costs, which can support future operating leverage as revenue scales. Maintaining this margin would give management a stronger path to narrowing losses while continuing investment in dermatology products.
Manageable LeverageModerate leverage and positive equity provide more financial flexibility than a highly indebted balance sheet would. This reduces immediate solvency pressure and leaves greater scope to fund development and commercialization, although continued losses could gradually weaken that position.
Bears Say
Heavy Operating LossesThe scale of operating and net losses shows that revenue growth has not yet translated into an economically sustainable business. Persistently negative margins can consume capital, limit strategic flexibility, and make the timing of breakeven dependent on substantial future operating improvement.
Persistent Cash BurnAlthough cash burn improved from 2024, ongoing negative operating and free cash flow means the company is not funding its activities internally. Continued reliance on external funding can dilute shareholders or increase financial obligations before the business reaches sustainable cash generation.
Eroding Equity BaseDeclining equity alongside deeply negative returns indicates that losses are reducing the capital base rather than generating productive returns. If this pattern persists, financial resilience may weaken and the company could face greater pressure to raise capital to support operations and growth.
Cutia Therapeutics News
2487 FAQ
What was Cutia Therapeutics’s price range in the past 12 months?
Cutia Therapeutics lowest stock price was HK$0.74 and its highest was HK$9.19 in the past 12 months.
What is Cutia Therapeutics’s market cap?
Cutia Therapeutics’s market cap is HK$385.77M.
When is Cutia Therapeutics’s upcoming earnings report date?
Cutia Therapeutics’s upcoming earnings report date is Mar 30, 2027 which is in 177 days.
How were Cutia Therapeutics’s earnings last quarter?
Cutia Therapeutics released its earnings results on Aug 31, 2026. The company reported -HK$0.584 earnings per share for the quarter.
Is Cutia Therapeutics overvalued?
According to Wall Street analysts Cutia Therapeutics’s price is currently Overvalued.
Does Cutia Therapeutics pay dividends?
Cutia Therapeutics does not currently pay dividends.
What is Cutia Therapeutics’s EPS estimate?
Cutia Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cutia Therapeutics have?
Cutia Therapeutics has 374,533,900 shares outstanding.
What happened to Cutia Therapeutics’s price movement after its last earnings report?
Cutia Therapeutics reported an EPS of -HK$0.584 in its last earnings report. Following the earnings report the stock price went down -2.302%.
Which hedge fund is a major shareholder of Cutia Therapeutics?
Currently, no hedge funds are holding shares in HK:2487
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cutia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cutia Therapeutics
Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, including medications for localized fat accumulation, advanced care for scalp disorders, treatments for a wide array of skin ailments, and topical pain management. Founded in 2019, the company's main headquarters are situated in Shanghai, China, complemented by additional offices located in Beijing, Wuxi, and Hong Kong.
Technical Analysis
JW (Cayman) Therapeutics Co. Ltd.
―
Mabpharm Limited
―
Sirnaomics Ltd.
―
SinoMab Bioscience Ltd.
―
Transcenta Holding Limited
―